ClinicalTrials.gg
TerminatedNCT06397313POTAMI-61Updated Sep 16, 2026

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

A Phase 2 interventional study of RVU120 and Ruxolitinib in Myelofibrosis, sponsored by Ryvu Therapeutics SA. Terminated at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Ryvu Therapeutics SA · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Primary Myelofibrosis with a site in Poland — 10 open to participants now, 20 under way, 10 of them phase 3. Primary Myelofibrosis · Poland.

Enrollment
30th of 33
36 · median 237
Started
2024
with 3 others
Phase 2
8 of 35
3 open now
Registered
31st of 35
by date

Among the 35 studies in Primary Myelofibrosis with a site in Poland, this one is the 30th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2024, is one of 8 in phase 2, and was the 31st registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

10 of the 35 studies in Primary Myelofibrosis with a site in Poland are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Primary Myelofibrosis with a site in Poland, or all of them as a file.
02

Study summary

The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.

Read the detailed description

The study schedule consists of a screening period up to 28 days, a 21-day treatment period, an end of treatment visit (30 days) and a 1-year follow-up where participants will be contacted every 3 months for assessment. Study duration for each participant will vary depending on the number of 21-day treatment cycles received. The study is open to participants aged ≥18 years with intermediate or high-risk, primary or secondary MF who have been previously treated, are ineligible for, or had a suboptimal response to JAK inhibitor therapy. Participants must have adequate organ function (kidney, liver) and no history of hematopoietic stem cell transplant. Participants may withdraw from the study at any time at their own request or may be withdrawn at any time at the discretion of the Investigator.

03

Conditions studied

  • Myelofibrosis

Keywords

  • intermediate
  • high-risk
  • primary
  • secondary
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Diagnosis of Primary or Secondary myelofibrosis (MF) according to the revised World Health Organization (WHO) criteria (Arber 2022).
  3. Intermediate or high-risk disease.
  4. Resistant or to prior Janus kinase (JAK) inhibitor treatment or ineligible for JAK inhibitor treatment in the opinion of the investigator; or Suboptimal response to JAK inhibitor treatment. Note: a suboptimal response to JAK inhibitor treatment is defined as spleen size increase by palpation >25% after the first 3 months of treatment with a JAK inhibitor or persistent splenomegaly (spleen volume of >450 cm3) after at least 6 months of JAK inhibitor treatment and presence of 1 symptom score ≥5 or 2 symptom scores ≥3, new or persistent red blood cell (RBC) transfusion dependence; or may include participants naïve to previous treatment with JAK inhibitor.
  5. Measurable splenomegaly as demonstrated by palpable spleen measuring ≥5 cm below the left costal margin. The edge of the spleen should be measured from the mid-clavicular line on the left side of the abdomen to the point of greatest splenic protrusion; or spleen volume of ≥450 cm3 measured by magnetic resonance imaging(MRI) or computed tomography (CT).
  6. Active symptoms of MF as demonstrated by a symptom score of at least 5 points (on a 0 to 10 scale) on at least one of the symptoms or a score of 3 or greater on at least 2 of the following symptoms: night sweats, itchiness, abdominal discomfort, pain under ribs on left side, early satiety, bone or muscle pain, and inactivity.
  7. (ECOG) performance score 0-2.
  8. Adequate hematologic function defined as:

    1. (ANC) ≥1.0 × 109/L (without growth factor support)
    2. count ≥50 × 109/L (Cohort 2 and Cohort 3 only)
  9. Adequate renal function defined as calculated or measured (CrCl) of ≥30 mL/minute using the formula of Cockcroft and Gault (see Section 15).
  10. Adequate liver function defined as (a) (AST) and alanine aminotransferase (ALT) ≤3 × (ULN); (b) alkaline phosphatase (ALP) ≤2 × ULN (ALP ≤5 × ULN for participants with isozymes specific to bone); (c) \<2 × ULN or bilirubin ≤3 × ULN if due to Gilbert's disease.

Exclusion criteria

Exclusion Criteria:

Each participant must not meet any of the following:

  1. Peripheral blood blast count of ≥10% or bone marrow blast count of ≥10%.
  2. Prior history of hematopoietic stem cell transplant.
  3. Participation in any other study in which receipt of an new drug occurred within 4 weeks prior to Cycle 1 Day 1.
  4. Active known second with the exception of any of the following:

    1. Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer
    2. Adequately treated Stage I cancer from which the participant is currently in remission and has been in remission for ≥2 years
    3. Low-risk prostate cancer with a Gleason score \<7 and a prostate-specific antigen (PSA) level \<10 ng/mL
    4. Any other cancer from which the participant has been disease-free for ≥3 years.
  5. Known or suspected allergy to RVU120 or RUX.
  6. Impairment of gastrointestinal function or gastrointestinal disease
  7. Major surgical procedure or significant traumatic injury within 28 days Placement of a vascular access device or minor surgery is permitted within 14 days before Cycle 1 Day 1 (provided that the wound has healed).
  8. Ongoing systemic infection requiring antibiotic, antiviral, or antifungal treatment. Note: prophylactic treatment is allowed.
  9. Significant cardiac dysfunction defined as myocardial infarction within 12 months of Cycle 1 Day 1, (NYHA) Class III or IV heart failure, uncontrolled dysrhythmias, poorly controlled angina (Section 17), or (LVEF) \<40% as per echocardiography or multiple gated acquisition (MUGA) scan.
  10. Taking any medications, herbal supplements, or other substances (including smoking) that are known to be strong inhibitors or moderate/strong inducers or sensitive substrates of CYP1A2, within less than 5 half-lives prior to Cycle 1 Day 1.
  11. History of ventricular arrhythmia, or ≥470 millisecond (Bazett's formula).
  12. Known active (HIV) infection
  13. Current active liver disease from any cause
  14. Pregnant or lactating females.
  15. Any other prior or current medical or psychiatric condition, intercurrent illness, surgical history, physical or (ECG) findings, laboratory abnormalities, or extenuating circumstance (e.g., alcohol or drug addiction) that, in the Investigator's opinion, could jeopardize participant safety or interfere with the objectives of the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    RVU120

    Cohort 1 RVU120 is administered at 250 mg as a single agent every other day on days 1, 3, 5, 7, 9, 11, and 13 of 21-day treatment cycles, or at an adjusted dose, to participants with intermediate or high-risk, primary or secondary MF who have been previously treated with or are ineligible for treatment with a JAK inhibitor.

    Drug: RVU120

  • Experimental
    RVU120 + ruxolitinib

    Cohort 2 RVU120 is administered at 250 mg every other day on days 1, 3, 5, 7, 9, 11, and 13 of 21-day treatment cycles or at an adjusted dose, in combined with ruxolitinib administered orally twice daily following the dosing instructions in current prescribing information, to participants with intermediate or high risk, primary or secondary MF experiencing suboptimal response to JAK inhibitor.

    Drug: RVU120 · Drug: Ruxolitinib

Interventions

  • DrugRVU120

    Drug pages: SEL-120 · Romaciclib · Silevertinib

    RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

    Also known as: SEL120

  • Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2

    Also known as: RUX

06

What researchers measure

Primary outcomes

  1. To evaluate the number of participants with a response (anti-cancer activity) to RVU120 when administered as a single agent or in combination with ruxolitinib

    The proportion of participants with spleen volume reduction (SVR) of ≥35% after 24 weeks of study treatment evaluated by magnetic resonance imaging (MRI) or computed tomography (CT)

    Time frame: 12 months

Secondary outcomes

  1. To further evaluate the number of participants having a response (anti-cancer activity and/or clinical benefit) to RVU120 when administered as a single agent or in combination with ruxolitinib

    The proportion of participants with ≥1 Grade bone marrow fibrosis improvement after 24 weeks of study treatment

    Time frame: 12 months

  2. Duration of spleen response

    Assessed as the time from initial SVR of ≥35% by MRI/CT until disease progression or death, whichever occurs first

    Time frame: 12 months

  3. Number of participants with leukemic transformation

    Assessed as the proportion of participants with bone marrow blast counts of at least 20%, or peripheral blast counts of at least 20% lasting 2 weeks

    Time frame: 12 months

  4. Number of participants with hematological (clinical) improvement

    Assessed as the proportion of participants with hematological (clinical) improvement as defined by International Working Group (IWG) Consensus Criteria (see Tefferi et al., 2006 for further details)

    Time frame: 12 months

  5. Progression-Free Survival (PFS)

    Assessed as time from the time from first treatment to the first occurrence of disease progression or death

    Time frame: 12 months

  6. Overall Survival (OS)

    Assessed as time from the time from first treatment to death

    Time frame: 12 months

  7. Incidence and severity of adverse events (AEs)

    Assessed as the number and grade of adverse events assessed by CTCAE v5.0

    Time frame: 12 months

  8. Change in symptom burden

    Assessed as the proportion of participants achieving at least a 50% reduction in symptom burden after 24 weeks of commencing study treatment as assessed by the Total Symptom Score (TSS) using the Myelofibrosis Symptom Assessment Form (MFSAF). Each item is rated on a scale from 0 (Absent) to 10 (Worst Imaginable).

    Time frame: Baseline and week 24

  9. Absolute change in TSS from baseline

    Assessed as the number of participants with absolute change in Total Symptom Score (TSS) from baseline assessed using the Myelofibrosis Symptom Assessment Form (MFSAF). Each item is rated on a scale from 0 (Absent) to 10 (Worst Imaginable).

    Time frame: Baseline and week 24

07

Study locations

18 sites
  • Policlinico Sant'Orsola-Malpighi
    Bologna, Italy
  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
    Brescia, Italy
  • Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco"
    Catania, Italy
  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l.
    Meldola, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milan, Italy
  • Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
    Biała Podlaska, Poland
  • Szpital Uniwersytecki nr 2 im. dr Jana Biziela
    Bydgoszcz, Poland
  • M2M Med. Sp. z o.o. Sp. j.
    Chorzów, Poland
  • Centrum Wsparcia Badań Klinicznych UCK Ośrodek Badań Klinicznych Wczesnych Faz
    Gdansk, Poland
  • Pratia Hematologia Sp. z o.o.
    Katowice, Poland
  • Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej
    Kielce, Poland
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
    Krakow, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie
    Lublin, Poland
  • Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu
    Torun, Poland
  • Lux Med Onkologia Sp. z o.o.
    Warsaw, Poland
  • Wojskowy Instytut Medyczny Państwowy Instytut Badawczy
    Warsaw, Poland
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
    Wroclaw, Poland
  • Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o.
    Zielona Góra, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Jun 2026, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 2, 2024
StartActual
Sep 19, 2024
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06397313
Lead sponsor
Ryvu Therapeutics SA
Responsible party
Sponsor
First posted
May 2, 2024
Start date
Sep 19, 2024
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Sep 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SEL-120 · Romaciclib · Silevertinib

Start the discussion